 NEW YORK, Dec. 14, 2020 GLOBE NEWSWIRE -- Mesoblast Limited Nasdaq:MESO; ASX:MSB, global leader in allogeneic cellular medicines for inflammatory diseases, today announced top-line results from the landmark DREAM-HF Phase 3 randomized controlled trial of its allogeneic cell therapy rexlemestrocel-L REVASCOR in 537 patients with advanced chronic heart failure1. 